罗氏将收购新一代测序技术酶工程公司Kapa Biosystems

  近日，罗氏(Roche)宣布了一项最终的协议，即收购分子生物酶类公司Kapa Biosystems，目前收购金额不详。
  Kapa公司总部在马萨诸塞州的威尔明顿市，而其研发和生产工厂在南非的开普敦市，该公司主要为新一代测序技术、PCR、实时定量PCR技术提供最优化的酶类。
  目前Kapa公司拥有一项专利化的蛋白质工程化技术，该技术可以帮助产生特殊酶类，进而改善多种反应的效率，包括用于对样品进行测序的新型DNA聚合酶等；上个月，Kapa公司就表示他们将为10X Genomics公司的GemCode平台供应准备试剂。
  罗氏诊断的首席运营官Roland Diggelmann说道，这项收购协议将基于罗氏的承诺，即开发分化的新一代测序技术组合，为消费者提供完全的基因检测溶液，这将会补充完善当前测序技术的缺陷，比如靶向作用目标产品。
  这项收购协议从属于特别的成交条件，将会增加到罗氏今年在基因组及分子诊断领域的其它收购项目中，包括对微生物诊断公司GeneWeave及癌症诊断公司CAPP Medical和Signature Diagnostics的收购。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Roche to Acquire Enzyme Engineering Firm Kapa Biosystems

Roche has signed a definitive agreement to acquire molecular biology enzyme firm Kapa Biosystems for an undisclosed amount, the company said today.

Kapa, headquartered in Wilmington, Massachusetts, with an R&D and manufacturing facility in Cape Town, South Africa, provides optimized enzymes for next-generation sequencing, PCR, and real-time PCR applications.

The company has a proprietary protein engineering technology to generate enzymes with improved performance for specific applications, including novel DNA polymerases for sequencing sample prep. Last month, for example, Kapa said it would supply library prep reagents for 10X Genomics' GemCode platform.

"This acquisition builds on Roche's commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution," said Roland Diggelmann, COO of Roche Diagnostics, in a statement, adding that it complements its existing NGS technology, such as target enrichment products.

The acquisition, which is subject to customary closing conditions, adds to other purchases by Roche in the areas of genomics and molecular diagnostics this year, including microbial diagnostics firm GeneWeave and cancer diagnostics companies CAPP Medical and Signature Diagnostics.